Salivary proteomic profile of patients with renal cell carcinoma.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 622-622
Author(s):  
Adithya Balasubramanian ◽  
Weidong Zhou ◽  
Emanuel Petricoin ◽  
Charles F. Streckfus ◽  
John R Klein ◽  
...  

622 Background: We aimed to explore the salivary proteomic profile (SPP) of patients undergoing surgery for suspected renal cell carcinoma (RCC), then evaluate any significant findings in a validation cohort. Methods: Prospective IRB approved trial of consecutive patients with suspected RCC undergoing curative surgery. Saliva was collected pre- and postoperatively, and from healthy volunteers. Saliva was mixed with sodium orthovanadate and protease inhibitor, aliquoted, and frozen at -80oC. SPP performed using biomarker concentrated saliva via core-shell hydrogel nanoparticles functionalized with molecular baits coupled to high resolution MS/MS electrospray mass spectrometry analysis; output represented as spectral counts. Wilcoxon Rank Sum test was used for comparisons; p-values were adjusted using false discovery rate (FDR) for multiple testing. Results: Exploratory phase: saliva was collected from 27 volunteers and 34 RCC patients (24 clear cell (cc)RCC, 6 chromophobe (ch)RCC, 4 other). Evaluation of cc vs chRCC revealed differential counts for 56 proteins; none were significant after adjustment by FDR. Comparison of matched pre/post-operative SPP in 14 ccRCC patients identified differential counts of 3 proteins: basic salivary proline-rich protein 3 precursor; prolactin-inducible protein precursor; and submaxillary gland androgen-regulated protein 3B precursor. These were not affected by patient age, partial/radical nephrectomy, or tumor size/stage/grade. Validation phase: power analyses indicated a sample size of 38/53 patients = 90% power = effect size of 0.6/0.5, respectively, 2-sided Type 1 error of 0.025. 49 ccRCC patients were enrolled with pre/postop saliva. 611 proteins were identified; none had differential counts after FDR. Conclusions: Using a unique biomarker technology coupled to high resolution MS, interesting SPP’s were seen between RCC subtypes and before/after ccRCC curative resection. We were unable to show significant differences in pre/post-op levels. More research is needed to further study the SPP in RCC patients and the factors impacting their differential expression. In order to aid such efforts, the raw data will be made available for future researchers.

Cancers ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 455 ◽  
Author(s):  
Seon-Hyeong Lee ◽  
Won-Kyu Lee ◽  
Nayeon Kim ◽  
Joon Kang ◽  
Kyung-Hee Kim ◽  
...  

In general, expression of transglutaminase 2 (TGase 2) is upregulated in renal cell carcinoma (RCC), resulting in p53 instability. Previous studies show that TGase 2 binds to p53 and transports it to the autophagosome. Knockdown or inhibition of TGase 2 in RCC induces p53-mediated apoptosis. Here, we screened a chemical library for TGase 2 inhibitors and identified streptonigrin as a potential therapeutic compound for RCC. Surface plasmon resonance and mass spectroscopy were used to measure streptonigrin binding to TGase 2. Mass spectrometry analysis revealed that streptonigrin binds to the N-terminus of TGase 2 (amino acids 95–116), which is associated with inhibition of TGase 2 activity in vitro and with p53 stabilization in RCC. The anti-cancer effects of streptonigrin on RCC cell lines were demonstrated in cell proliferation and cell death assays. In addition, a single dose of streptonigrin (0.2 mg/kg) showed marked anti-tumor effects in a preclinical RCC model by stabilizing p53. Inhibition of TGase 2 using streptonigrin increased p53 stability, which resulted in p53-mediated apoptosis of RCC. Thus, targeting TGase 2 may be a new therapeutic approach to RCC.


2013 ◽  
Vol 54 (12) ◽  
pp. 830 ◽  
Author(s):  
Hyuk Jun Kong ◽  
Jae Shin Park ◽  
Duk Yoon Kim ◽  
Hong Seok Shin ◽  
Hyun Jin Jung

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16097-16097 ◽  
Author(s):  
J. Mardiak ◽  
M. Mego ◽  
D. Urbanova ◽  
B. Mladosievicova ◽  
J. Postulka ◽  
...  

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15000-e15000 ◽  
Author(s):  
C. Y. Hu ◽  
D. Mohtat ◽  
Y. Yu ◽  
T. Bhagat ◽  
C. J. Heuck ◽  
...  

2003 ◽  
Vol 180 (5) ◽  
pp. 1271-1277 ◽  
Author(s):  
C. Catalano ◽  
F. Fraioli ◽  
A. Laghi ◽  
A. Napoli ◽  
F. Pediconi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document